Interestingly, the mutant KRAS-driven GBCs predominantly led to adenocarcinomas with tubular structures whereas the ERBB2-driven GBC frequently showed a pronounced tubulo-papillary/papillary differentiation. Here, KRAS is linked to adenocarcinoma.